Cellectis (CLLS) Enterprise Value (2013 - 2026)
Cellectis (CLLS) posted quarterly Enterprise Value of -$185.7 million for Q1 2026, up 23.81% year-over-year from -$150.0 million in Q1 2025, and up 11.02% quarter-over-quarter from -$208.7 million in Q4 2025.
Cellectis (CLLS) Enterprise Value (2013 - 2026) Analysis & Trends
Cellectis' Enterprise Value history runs 14 years deep, the most recent figure standing at -$185.7 million for Q1 2026.
- In Q1 2026, Enterprise Value rose 23.81% year-over-year to -$185.7 million; the TTM figure through Mar 2026 stood at -$185.7 million (up 23.81% YoY), while the FY2025 annual figure was -$208.7 million, up 48.87% from the prior year.
- Enterprise Value for Q1 2026 stood at -$185.7 million, up from -$208.7 million in the prior quarter.
- The five-year high for Enterprise Value was -$67.4 million in Q3 2023, with the low at -$408.1 million in Q4 2024.
- The 5-year median for Enterprise Value is -$192.2 million (2025), against an average of -$196.8 million.
- The sharpest annual moves came in 2024 and 2025: Enterprise Value plunged 287.4% in 2024, then soared 48.87% in 2025.
- Cellectis' Enterprise Value stood at -$187.7 million in 2022, then plunged by 83.94% to -$345.2 million in 2023, then slipped by 18.23% to -$408.1 million in 2024, then jumped by 48.87% to -$208.7 million in 2025, then advanced by 11.02% to -$185.7 million in 2026.
- Business Quant data shows CLLS's Enterprise Value at -$185.7 million in Q1 2026, -$208.7 million in Q4 2025, and -$192.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Cellectis | 306.61 Mn | 120.95 Mn | - | -185.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -185.66 Mn |
| Dec 31, 2025 | -208.66 Mn |
| Sep 30, 2025 | -192.22 Mn |
| Jun 30, 2025 | -198.15 Mn |
| Mar 31, 2025 | -243.69 Mn |
| Dec 31, 2024 | -408.11 Mn |
| Sep 30, 2024 | -260.95 Mn |
| Jun 30, 2024 | -272.81 Mn |
| Mar 31, 2024 | -213.10 Mn |
| Dec 31, 2023 | -345.18 Mn |
| Sep 30, 2023 | -67.36 Mn |
| Jun 30, 2023 | -85.49 Mn |
| Mar 31, 2023 | -81.41 Mn |
| Dec 31, 2022 | -187.66 Mn |
| Sep 30, 2022 | -110.04 Mn |
| Jun 30, 2022 | -142.04 Mn |
| Mar 31, 2022 | -143.36 Mn |
| Dec 31, 2021 | -170.95 Mn |
| Sep 30, 2021 | -186.92 Mn |
| Jun 30, 2021 | -225.16 Mn |